Erickson-Johnson et al used copy numbers of MDM2 and CPM in tumor cells to distinguish well-differentiated liposarcoma/atypical lipomatous tumors from lipomas. The authors are from Mayo Clinic in Rochester.
MDM2 (p53 binding protein) is a gene on chromosome 12q13-15 that is amplified in well-differentiated liposarcomas/atypical lipomatous tumors. It may also be amplified in other forms of sarcoma.
CPM (carboxypeptidase M) is another gene on chromosome 12q13-15 that is amplified in well-differentiated liposarcomas/atypical lipomatous tumors.
Method used to evaluate tumors: FISH
Genetic studies performed in 100+ tumor cells:
(1) chromosome number
(2) copies of MDM2 (marker gene)
(3) copies of CPM (marker gene)
(3) copies of CEP12 (reference gene)
(4) copies of SYT10 (reference gene)
ratio of copies for MDM2 to CEP12 =
= (copies of MDM2) / (copies of CEP12)
ratio of copies for CPM to CEP12 =
= (copies of CPM) / (copies of CEP12)
ratio of copies for CPM to SYT10 =
= (copies of CPM) / (copies of SYT10)
|
Percent Cells with MDM2/CEP12 >= 3 |
Percent Cells with CPM/CEP12 >= 3 |
Percent Cells with CPM/SYT10 >= 3 |
Interpretation |
|
> 10% |
NA |
NA |
amplification |
|
NA |
> 10% |
NA |
amplification |
|
NA |
NA |
> 10% |
amplification |
|
< 10% |
< 10% |
< 10% |
nonamplification |
A tumor shows aneuploidy if the chromosome number is not an exact multiple of the haploid set of chromosomes.
|
Amplification |
Aneuploidy |
Association |
|
present |
absent |
well-differentiated liposarcoma or atypical lipomatous tumor |
|
absent |
present |
pleomorphic lipoma, myxoid liposarcoma |
|
absent |
absent |
pleomorphic liposarcoma, lipoma |
Specialty: Hematology Oncology, Surgery, general, Surgery, orthopedic
ICD-10: ,
